CLDX - CIK 0000744218
Celldex Therapeutics, Inc. trades as CLDX and has a market capitalization of $2.30 B, making it the #1998 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $1.54M, down 78.0% from the prior year and net income of -$258.76M. This page tracks Celldex Therapeutics, Inc. through 1,268 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years Celldex Therapeutics, Inc.'s revenue declined from $6.79M to $1.54M, a compound annual decline rate of 15.2%. Net profit margin compressed from -1516.0% to -16748.0% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-12 |
| Major company event | 8-K | 2026-05-07 |
| Quarterly report | 10-Q | 2026-05-07 |
| SCHEDULE 13G/A | - | 2026-05-06 |
| SCHEDULE 13G | - | 2026-04-29 |
| Annual report to shareholders | ARS | 2026-04-29 |
Celldex Appoints Freddy A. Jimenez, Esq. as Senior Vice President and General Counsel | Celldex Therapeutics
Celldex Doses First Patient in Phase 1b Study of CDX-0159 in Chronic Inducible Urticaria | Celldex Therapeutics
Celldex Therapeutics to Present at 3rd Annual Evercore ISI HealthCONx Conference | Celldex Therapeutics
Celldex Presents Data from Oncology Portfolio at SITC 2020 | Celldex Therapeutics
Celldex Provides Corporate Update and Reports Third Quarter 2020 Results | Celldex Therapeutics
The largest companies sharing Celldex Therapeutics, Inc.'s SEC industry classification (in vitro & in vivo diagnostic substances).
Celldex Therapeutics, Inc. (CLDX) has a market capitalization of $2.30 B as of 2026-06-10, ranking #1998 among US-listed companies.
Celldex Therapeutics, Inc. reported revenue of $1.54M for fiscal year 2025, a decrease of 78.0% year over year.
In its latest fiscal year Celldex Therapeutics, Inc. reported a net loss of $258.76M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.